

# RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 29 JUNE 2023

Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 15,032,834

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: **13.046,120** 

# That means a quorum of 86.78% of the 15,032,834 shares with voting rights: <u>the Ordinary Annual General Meeting was able to deliberate</u>.

The Ordinary Annual General Meeting was held on Thursday, 29 June 2023 at 5:30 p.m. at the Company's headquarters and approved the separate parent company and consolidated financial statements for the 2022 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions	Results of the votes
RESOLUTION ONE     Approval of the annual financial statements	Resolution adopted by: - 13,044,237 votes in favour - 0 vote against - 1,883 abstentions
<ul> <li>RESOLUTION TWO         Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement     </li> </ul>	Resolution adopted by: - 12,943,792 votes in favour - 100,445 votes against - 1,883 abstentions
RESOLUTION THREE     Approval of the consolidated financial statements	Resolution adopted by: - 13,044,237 votes in favour - 0 vote against - 1,883 abstentions
<ul> <li>RESOLUTION FOUR Appropriation of earnings, setting the dividend</li> </ul>	Resolution adopted by: - 13,046,120 votes in favour - 0 vote against - 0 abstention
<ul> <li>RESOLUTION FIVE         Agreements and commitments governed by Articles L.         225-38 of the French Commercial Code</li> </ul>	Resolution adopted by (*):  - 12,983,939 votes in favour  - 62,072 votes against  - 99 abstentions



<ul> <li>RESOLUTION SIX         Renewal of Ms. Anne LHOTE's term of office as         Director</li> </ul>	Resolution adopted by: - 10,706,967 votes in favour - 2,339,153 votes against - 0 abstention
<ul> <li>RESOLUTION SEVEN         Renewal of Ms. Céline GRIS's term of office as Independant Director     </li> </ul>	Resolution adopted by: - 11,112,739 votes in favour - 1,933,381 votes against - 0 abstention
RESOLUTION EIGHT     Renewal of Ms. Émilie LECOMTE's term of office as     Director	Resolution adopted by: - 10,723,209 votes in favour - 2,322,911 votes against - 0 abstention
<ul> <li>RESOLUTION NINE Appointment of a new Director</li> </ul>	Resolution adopted by: - 12,902,756 votes in favour - 143,364 votes against - 0 abstention
RESOLUTION TEN     Appointment of a new Statutory Auditor	Resolution adopted by: - 13,040,577 votes in favour - 5,543 votes against - 0 abstention
<ul> <li>RESOLUTION ELEVEN         Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2022 and mentioned in Article L. 22-10-9 of the French Commercial Code     </li> </ul>	Resolution adopted by: - 12,095,451 votes in favour - 950,669 votes against - 0 abstention
<ul> <li>RESOLUTION TWELVE         Approval of the components of compensation paid in 2022 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors     </li> </ul>	Resolution adopted by: - 13,033,420 votes in favour - 12,700 votes against - 0 abstention
<ul> <li>RESOLUTION THIRTEEN         Approval of the components of compensation paid in 2022 to Mr. Dominique PAUTRAT, Chief Executive Officer     </li> </ul>	Resolution adopted by: - 10,746,386 votes in favour - 2,299,734 votes against - 0 abstention
<ul> <li>RESOLUTION FOURTEEN         Approval of the components of compensation paid in 2022 to Mr. Denis SUPPLISSON, Deputy Chief Executive Officer and then Chief Executive Officer     </li> </ul>	Resolution adopted by: - 10,592,005 votes in favour - 2,454,115 votes against - 0 abstention
<ul> <li>RESOLUTION FIFTEEN         Approval of the components of compensation paid in 2022 to Mr. Grégoire DE ROTALIER, Deputy CEO     </li> </ul>	Resolution adopted by: - 10,592,005 votes in favour - 2,454,115 votes against - 0 abstention
<ul> <li>RESOLUTION SIXTEEN         Approval of the compensation policy for the Chairman of the Board of Directors for 2023     </li> </ul>	Resolution adopted by: - 13,033,420 votes in favour - 12,700 votes against - 0 abstention



	RESOLUTION SEVENTEEN Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2023	Resolution adopted by: - 10,759,416 votes in favour - 2,286,704 votes against - 0 abstention
•	RESOLUTION EIGHTEEN Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2023	Resolution adopted by: - 10,759,416 votes in favour - 2,286,704 votes against - 0 abstention
•	RESOLUTION NINETEEN Approval of the compensation policy for Directors	Resolution adopted by: - 13,044,420 votes in favour - 1,700 votes against - 0 abstention
•	RESOLUTION TWENTY Setting total annual compensation for Directors for 2023	Resolution adopted by: - 13,044,420 votes in favour - 1,700 votes against - 0 abstention
•	RESOLUTION TWENTY-ONE Authorisation by the Company to repurchase its own shares	Resolution adopted by: - 11,101,214 votes in favour - 1,944,906 vote against - 0 abstention
•	RESOLUTION TWENTY-TWO Powers for formalities	Resolution adopted by: - 13,046,120 votes in favour - 0 vote against - 0 abstention

<sup>(\*)</sup> After deduction of excluded voting rights

#### **Financial Calendar:**

- Publication of H1 2023 Revenue: 3 August 2023, after French market closure.

#### **About Group Equasens**

Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "technology for a more human experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.



#### Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable Included in the Euronext Tech Leaders segment and the European Rising Tech label



Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)

ISIN: FR 0012882389 - Ticker Code: EQS



Get all the news about the Equasens Group <u>www.equasens.com</u> and on <u>LinkedIn</u>

## **CONTACTS**

#### **Analyst and Investor Relations:**

Chief Administrative and Financial Officer: Frédérique SCHMIDT Tel. +33 (0)3 83 15 90 67 - <a href="mailto:frederique.schmidt@equasens.com">frederique.schmidt@equasens.com</a>

## Media Relations:

FIN'EXTENSO - Isabelle APRILE

Tel. +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr